(Q39494507)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

The impact of molecular targets in cancer drug development: major hurdles and future strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Alexandra Hebar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Edgar Selzer

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

1 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Pharmacology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

23-34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

Personalized medicine in oncology: the future is now.

21 February 2020

cites work

1 reference

Cancer Chemotherapy with Purine and Pyrimidine Analogues

21 January 2018

1 reference

Drug discovery: a historical perspective

21 January 2018

1 reference

Paul Ehrlich's magic bullet concept: 100 years of progress.

21 January 2018

1 reference

A brief history of great discoveries in pharmacology: in celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics

21 January 2018

1 reference

The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole

21 January 2018

1 reference

Anticancer drug development: the grand challenges.

21 January 2018

1 reference

Why is cancer drug discovery so difficult?

21 January 2018

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

New approaches to molecular cancer therapeutics

21 January 2018

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Advances in the preclinical testing of cancer therapeutic hypotheses.

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

The Phase III Trial in the Era of Targeted Therapy: Unraveling the “Go or No Go” Decision

21 January 2018

1 reference

Impact of molecular targets in cancer drug development: historical influence and future perspectives

21 January 2018

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

Molecular subtypes in breast cancer evaluation and management: divide and conquer

21 January 2018

1 reference

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

Clonal evolution in cancer

21 January 2018

1 reference

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.

21 January 2018

1 reference

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

Clinical trials for predictive medicine

21 January 2018

1 reference

Clinical trials for predictive medicine: new challenges and paradigms

21 January 2018

1 reference

Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design

21 January 2018

1 reference

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

21 January 2018

1 reference

The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding

21 January 2018

1 reference

Crystallization of protein-ligand complexes.

21 January 2018

1 reference

Protein crystallization: from purified protein to diffraction-quality crystal

21 January 2018

1 reference

Update on Anti-EGFR Therapy.

21 January 2018

1 reference

The ERBB network: at last, cancer therapy meets systems biology.

21 January 2018

1 reference

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

21 January 2018

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

21 January 2018

1 reference

Cancer stem cells: lessons from leukaemia

21 January 2018

1 reference

Cancer stem cells: models and concepts

21 January 2018

1 reference

Self-renewal and solid tumor stem cells

21 January 2018

1 reference

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

21 January 2018

1 reference

Stochastic dynamics of hematopoietic tumor stem cells.

21 January 2018

1 reference

Effect of cellular quiescence on the success of targeted CML therapy

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding

21 January 2018

1 reference

Aptamers for allosteric regulation

21 January 2018

1 reference

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

21 January 2018

1 reference

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

21 January 2018

1 reference

Elucidating mechanisms of drug-induced toxicity.

21 January 2018

1 reference

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

The NCI60 human tumour cell line anticancer drug screen

21 January 2018

1 reference

Leader of the pack: gene mapping in dogs and other model organisms

21 January 2018

1 reference

Translation of new cancer treatments from pet dogs to humans

21 January 2018

1 reference

First dose of potential new medicines to humans: how animals help

21 January 2018

1 reference

21 January 2018

2011 FDA drug approvals

1 reference

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

Making better drugs: Decision gates in non-clinical drug development

21 January 2018

1 reference

How were new medicines discovered?

21 January 2018

1 reference

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

Harnessing synthetic lethal interactions in anticancer drug discovery

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.12.71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23272790%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference